Featured

Sanofi Buys Vigil In $470 Million Deal For Alzheimer’s TREM2 Drug

UroGen Draws A Split Adcom Panel Vote For Bladder Cancer Drug UGN-102

Pfizer Wants To Throw Its Hat Into The Ring With Up To $6 Billion 3SBio Deal

Prime Medicine Not Keen On PM359 Advancement Despite Initial Data

CRISPR Scores Win For CTX310 Targeting Cholesterol Patients

Vertex Pauses Study Of VX-522 For Patients With Cystic Fibrosis

Eli Lilly’s Orforglipron Delivers Efficacy Similar To That Of Injectable GLP-1 Drugs

Bristol-Myers Squibb Puts Its Hat Into The Ring In Targeting 1st-Line Liver Cancer With OPDIVO-Based Regimen

Cassava Sciences Scraps Alzheimer’s Drug Development Of Simufilam After Latest Trial Failure

Scroll to Top